Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Performance of the Cardiac Microcurrent (C-MIC) System With a Less Invasively Placed Left Ventricular Lead
- Conditions
- Idiopathic CardiomyopathyLeft Ventricular (LV) Systolic Dysfunction
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Berlin Heals GmbH
- Target Recruit Count
- 33
- Registration Number
- NCT06920030
- Locations
- 🇧🇦
University Clinical Center of the Republic of Srbska, Banja Luka, Republic of Srbska, Bosnia and Herzegovina
🇷🇸Institute of Cardiovascular Disease Dedinje, Belgrade, Serbia
The C-MIC-II Follow-Up Study
- Conditions
- Systolic Left Ventricular Dysfunction
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Berlin Heals GmbH
- Target Recruit Count
- 31
- Registration Number
- NCT05189860
- Locations
- 🇲🇰
University Clinic Cardiac Surgery, Skopje, North Macedonia
🇧🇦University Clinical Centre of Republic of Srpska, Banja Luka, Bosnia and Herzegovina
🇧🇦University Clinical Center of Sarajevo, Sarajevo, Bosnia and Herzegovina
Performance and Safety of the Cardiac Microcurrent Therapy System
- Conditions
- Systolic Left Ventricular Dysfunction
- Interventions
- Device: CMICDrug: Standard of Care (SOC)
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Berlin Heals GmbH
- Target Recruit Count
- 70
- Registration Number
- NCT04662034
- Locations
- 🇧🇦
University Clinic, Banja Luka, Bosnia and Herzegovina
🇧🇦University Clinic Sarajevo, Sarajevo, Bosnia and Herzegovina
🇧🇬Diagnostic and Consultative Center Neoclinic Ead, Sofia, Bulgaria
News
C-MIC II Trial Shows Microcurrent Therapy Significantly Improves Heart Function in Heart Failure Patients
The C-MIC II randomized controlled trial demonstrated that microcurrent therapy significantly improved left ventricular ejection fraction by 5.1% compared to controls in heart failure patients with reduced ejection fraction.